Insulin-like growth factor (IGF)-binding protein-4 (IGFBP-4) is secreted by a variety of osteoblastic cells and appears to be an integral component of bone cell physiology. We have previously reported that normal human osteoblast-like (hOB) cells secrete
IGFBP-4 as well as a novel
IGFBP-4 protease, which requires IGF for functional activity. In this study we assessed the
IGFBP-4/
IGFBP-4 protease system in transformed osteoblastic cells by Western
ligand blotting and cell-free
IGFBP-4 protease assays. Simian virus-40-immortalized hOB cells (HOBIT), human
osteosarcoma cells (TE-85), and rat
osteosarcoma cells (UMR 106-01, ROS 17/2.8) secrete
IGFBP-4. In contrast to the rapid and dramatic proteolysis in hOB medium,
medium conditioned by these cells had no apparent
IGFBP-4 protease activity when assayed with exogenous
IGF-II in culture or under cell-free conditions. Assayed in the presence of exogenous
protease. HOBIT cells, but not the
osteosarcoma cell lines, appeared to produce a
cycloheximide-sensitive inhibitor of the
IGFBP-4 proteolytic reaction. Transient cell transformation induced by incubating human osteoblasts transfected with a temperature-sensitive mutant of simian virus-40
T-antigen at the permissive temperature or by treating hOB cells with
phorbol ester tumor promoters also resulted in inhibition of IGF-dependent
IGFBP-4 proteolysis. Inhibition was observed if
phorbol ester was added to the cultures at the time of medium change or after the
protease had been expressed and secreted. Differences in
IGFBP-4 proteolysis could not be accounted for by changes in
IGFBP-4 messenger RNA expression or substrate levels. These data suggest that transformation is associated with alterations in the
IGFBP-4/
IGFBP-4 protease system in osteoblastic cells. Normal human osteoblasts secrete an IGF-dependent
IGFBP-4 protease. The induction of an inhibitor of the IGF-dependent
IGFBP-4 proteolytic reaction may be associated with early transformation processes. Fully tumorigenic bone cells expressed neither
IGFBP-4 protease nor
protease inhibitor activity.